Today's Reuters Health News Headlines - Yahoo! News:
|
|
Former lab technician charged in New Hampshire hepatitis C outbreak
Sat,21 Jul 2012 09:18 AM PDT
Reuters - (Reuters) - A former lab technician faces charges in connection with a hepatitis C outbreak that reportedly infected dozens of patients at a New Hampshire hospital, authorities said. David Michael Kwiatkowski, 32, is charged with obtaining controlled substances by fraud and tampering with a consumer product, U.S. Attorney John P. Kacavas said this week. The outbreak at the Exeter Hospital Cardiac Catheterization Unit is believed to have infected some 30 people with the disease, considered the most serious of hepatitis strains, authorities said. ... Full Story | Top |
Nothing but net? Basketball science has more answers
Sat,21 Jul 2012 07:14 AM PDT
Reuters -  (This is the seventh in a series of stories about the science behind the Olympics to run daily this week.) NEW YORK (Reuters) - In a multibillion-dollar sport like basketball, one might expect trainers had figured out every nuance of aerodynamics, mechanics and all things Newtonian to increase the rate at which the ball goes through the hoop. Think again. Take free throws. For 50 years professional players in the United States have sunk these shots from the "charity line" - so called because the points are supposedly such sure things they're gifts - at a rate of about 75 percent. ...
Full Story | Top |
U.S. appeals court reconsiders Myriad gene patent ruling
Fri,20 Jul 2012 04:25 PM PDT
Reuters - WASHINGTON (Reuters) - Myriad Genetics Inc illegally patented acts of nature when it claimed ownership of two genes linked to cancer, the federal government told an appeals court on Friday. Lawyers from Myriad, as well as the American Civil Liberties Union and the U.S. Patent and Trademark Office appeared in the U.S. Court of Appeals for the Federal Circuit at the direction of the U.S. Supreme Court in order to examine the impact of Mayo v. Prometheus, the high court's March ruling that companies cannot patent observations about nature. ... Full Story | Top |
WHO endorses use of HIV medicines for prevention
Fri,20 Jul 2012 02:18 PM PDT
Reuters - NEW YORK (Reuters) - The World Health Organization has endorsed using HIV medicines among people who do not have the infection but are at high risk of getting it and suggested that poor and wealthy countries alike set up pilot projects to better understand the benefits. The United Nations agency made its suggestion on Friday, four days after U.S. regulators approved use of Gilead Sciences Inc's Truvada for people who are not infected but may engage in sexual activity with HIV-positive partners. The concept is known as pre-exposure prophylaxis, or PrEP. ... Full Story | Top |
Mom's nut consumption tied to less allergy in kids
Fri,20 Jul 2012 02:01 PM PDT
Reuters - NEW YORK (Reuters Health) - In a study based on 62,000 Danish mothers, the children of those who ate peanuts and tree nuts while pregnant were less likely to develop asthma or allergies than the kids whose mothers shunned nuts. The results support the recent withdrawal of recommendations that pregnant women should avoid nuts because they might raise a child's risk for allergies to the nuts themselves and for other hypersensitivities like asthma, according to the U.S. and Danish researchers. ... Full Story | Top |
FDA OKs Onyx's Kyprolis for multiple myeloma
Fri,20 Jul 2012 01:22 PM PDT
Reuters - WASHINGTON (Reuters) - U.S. drug regulators approved Onyx Pharmaceuticals Inc's Kyprolis for people with a type of blood cancer that has failed to respond to other medicines. The U.S. Food and Drug Administration said on Friday the intravenous drug was approved for treating multiple myeloma in people who have tried at least two other medicines, including Takeda Pharmaceutical Co Ltd's Velcade and Celgene Corp's Revlimid or Thalomid. Multiple myeloma, a type of cancer that affects the plasma cells in bone marrow, is relatively rare in the United States but often deadly. ... Full Story | Top |
FDA approves Novartis drug Afinitor for breast cancer
Fri,20 Jul 2012 01:21 PM PDT
Reuters - (Reuters) - The U.S. Food and Drug Administration on Friday approved Novartis AG drug Afinitor to treat women with a certain type of breast cancer. The drug is the first in a class known as mTOR inhibitors to be approved for post-menopausal women with advanced hormone-receptor positive, HER2-negative breast cancer. The European Medicines Agency in June also endorsed Afinitor as a breast cancer treatment. ... Full Story | Top |
Western fast food tied to heart risks in Asia
Fri,20 Jul 2012 01:17 PM PDT
Reuters - NEW YORK (Reuters Health) - Even relatively clean-living Singaporeans who regularly eat burgers, fries and other staples of U.S.-style fast food are at raised risk of diabetes and significantly more likely than peers to die of heart disease, according to a new study. With globalization, fast food - widely regarded as nutritionally poor - has become commonplace in East and Southeast Asia. But there's been little research into the effects of western junk food on the health of non-western populations, especially those transitioning to more-prosperous lifestyles. ... Full Story | Top |
Most women return to work after breast cancer
Fri,20 Jul 2012 10:20 AM PDT
Reuters - NEW YORK (Reuters Health) - Women who were in the workforce before a breast cancer diagnosis often get back to their normal job routine after treatment, a study of Swedish women finds. Researchers found that of 505 women treated for breast cancer, three-quarters were employed 16 months after their diagnosis - which is in line with the rate of employment among Swedish women in general. And of women who were working before their diagnosis, 72 percent went back without any change in their schedules. Fifteen percent had cut back on their hours, while 11 percent had not gone back at all. ... Full Story | Top |
Analysis: Small generic drug firms need niches to survive looming price war
Fri,20 Jul 2012 09:52 AM PDT
Reuters - (Reuters) - Aggressive consolidation among U.S. and European generic drugmakers is putting pressure on smaller competitors in the industry, whose best hope of surviving a brewing price war may lie in finding specialized niches. Expiring patents on some of Big Pharma's top-selling drugs is about to flood the market with cheaper copies, driving dealmaking among larger generics makers like Teva Pharmaceutical Industries Ltd, Novartis's Sandoz, Mylan Inc and Watson Pharmaceuticals Inc to gain economies of scale. ... Full Story | Top |
Even without anemia, iron may help fatigue
Fri,20 Jul 2012 09:29 AM PDT
Reuters -  NEW YORK (Reuters Health) - Some women with unexplained fatigue may get a bit more pep from iron supplements - even if they do not have full-blown anemia, a new clinical trial suggests. The study focused on women who were chronically tired and had relatively low iron stores. They did not, however, have full-blown iron-deficiency anemia, in which the body has too few oxygen-carrying red blood cells. It has not been clear whether iron supplements can help battle fatigue in non-anemic women. ...
Full Story | Top |
Pray for headwinds in the discus
Fri,20 Jul 2012 09:04 AM PDT
Reuters -  NEW YORK (Reuters) - For an event featured 2,719 years ago in the first pentathlon, the discus throw is long overdue for an analysis more sophisticated than "chuck it as hard as you can". Thanks to several new three-dimensional studies in biomechanics labs, the ancient event is finally getting its due. Based on the latest findings, fans hoping to see a new world record should pray for headwinds. The world's first Frisbee, the discus gets most of its distance from the angle of its rising trajectory and its speed at release. ...
Full Story | Top |
Celgene to appeal negative European opinion on Istodax
Fri,20 Jul 2012 08:39 AM PDT
Reuters - (Reuters) - Celgene Corp said on Friday it plans to ask a European advisory panel to reconsider its decision not to recommend approval of the company's treatment for relapsed or refractory peripheral t-cell lymphoma (PTCL). The news sent Celgene's shares down as much as 2 percent. Celgene submitted an application for approval of the drug, Istodax, based on an open-label mid-stage study, meaning there was no comparator arm in the trial. The U.S. ... Full Story | Top |
Staar Surgical shares fall on weak revenue estimate
Fri,20 Jul 2012 08:14 AM PDT
Reuters - (Reuters) - Shares of Staar Surgical Co lost more than a fifth of their value after the company estimated second-quarter revenue below analysts' expectations. Staar's stock was down about 21 percent at $6.37 on Friday on the Nasdaq, its biggest single-day percentage drop in three-and-a-half years. It touched a low of $6.19 earlier in the day. At least two brokerages cut their price targets on the stock citing weak sales outlook for Staar's Visian ICL lenses. ... Full Story | Top |
Hospitals hype robot surgery for women: study
Fri,20 Jul 2012 08:02 AM PDT
Reuters - NEW YORK (Reuters Health) - Consumers shouldn't expect straight talk about robot surgery from hospital websites, but rather vague claims and marketing mantras, according to a new U.S. study. Researchers sifted through online information from 432 hospitals across the country and found nearly half marketed robotic surgery for gynecologic conditions such as endometriosis or cervical cancer. A quarter of those hospitals used boilerplate copy from the robot manufacturer Intuitive Surgical, and one in six told consumers that "you owe it to yourself. ... Full Story | Top |
| |
|
No comments:
Post a Comment